XH-S004 / Fosun Pharma, Expedition Therapeutics - LARVOL DELTA

Global R&D | Fosun Pharma's self-developed Class 1 new drug XH-S004 has initiated a phase Ib clinical trial for the treatment of chronic obstructive pulmonary disease [Google translation] (Fosun Pharma Press Release) - "On July 17, Fosun Pharma...announced that the Class 1 new drug XH-S004 (the new drug) independently developed by its holding subsidiary Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd. ('Xinghao Pengbo') for the treatment of chronic obstructive pulmonary disease (COPD) has recently launched a phase Ib clinical trial in China (excluding Hong Kong, Macao and Taiwan)."

Trial status • Chronic Obstructive Pulmonary Disease

Fosun Pharma’s Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million (PRNewswire) - "Fosun Pharma will retain the rights to develop, manufacture, and commercialize XH-S004 in Chinese Mainland, Hong Kong SAR and Macau SAR. Under the agreement, Expedition will pay Fosun Pharma up to US$120 million including upfront payment and development milestone payments. In addition, based on the annual net sales of XH-S004 in the licensed territories, Expedition will pay up to US$525 million in sales milestone payments as stipulated in the contract."

Licensing / partnership • Chronic Obstructive Pulmonary Disease • Non‐Cystic Fibrosis Bronchiectasis

The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations (clinicaltrials.gov) - P1 | N=81 | Not yet recruiting | Sponsor: S-INFINITY Pharmaceuticals Co., Ltd

New P1 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis (clinicaltrials.gov) - P2 | N=231 | Not yet recruiting | Sponsor: S-INFINITY Pharmaceuticals Co., Ltd

New P2 trial • Bronchiectasis • Genetic Disorders • Immunology • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

A Phase I Study of XH-S004 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=90 | Not yet recruiting | Sponsor: S-Infinity Pharmaceuticals Co., Ltd

New P1 trial